PARP1 and neoplasm: PARP inhibitors have been shown to have specific efficacy against tumours with BRCA1/2 mutations, leading to the subsequent success of the use of PARP inhibitors in the treatment of certain tumours with BRCA mutation and HR deficiency 50.